Synthesis and pharmacological evaluation of novel arylpiperazine derivatives as nonsteroidal androgen receptor antagonists

Chem Pharm Bull (Tokyo). 2004 Nov;52(11):1330-3. doi: 10.1248/cpb.52.1330.

Abstract

The search for novel antiandrogens by high-throughput screening (HTS) of the Yamanouchi chemical library led to the discovery of the lead compound (5), which possesses an arylmorpholine moiety. Through the optimization of the lead compound (5), we have found a series of novel arylpiperazine derivatives. Among them, 4-[4-cyano-(3-trifluoromethyl)phenyl]-N-(4-fluorophenyl)piperazine-1-carboxamide (22; YM-92088) exhibited a potent AR antagonistic activity with an IC(50) value of 0.47 microM in the reporter assay, which is more potent than bicalutamide (4) which has an IC(50) value of 0.89 microM.

MeSH terms

  • Androgen Receptor Antagonists*
  • Animals
  • CHO Cells
  • Cricetinae
  • Drug Evaluation, Preclinical / methods
  • Humans
  • Piperazines / chemical synthesis*
  • Piperazines / pharmacology*
  • Receptors, Androgen / biosynthesis

Substances

  • Androgen Receptor Antagonists
  • Piperazines
  • Receptors, Androgen